falimarev
Vaccineexperimental
Clinical trial activity
6 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
4
Phase 3
1
Phase 4
0
Earliest trial started Jun 1, 2004 (NCT00088660)
Timeline
Indications
Mechanism of action
- Mucin-1Immunity, active
MUC1 immunity, active
- Carcinoembryonic antigen-related cell adhesion molecule 5Immunity, active
CEACAM5 immunity, active
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2108609 ↗
Also known as
- falimarev
- inalimarev (cea, muc-1, vaccinia virus)
- panvac
- panvac
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02015104 | Phase 2 | Dec 12, 2013 | National Cancer Institute (NCI), Rutgers University |
| NCT00669734 | Phase 1 | Feb 1, 2010 | National Cancer Institute (NCI), Rutgers University |
| NCT00179309 | Phase 2 | Sep 1, 2005 | National Cancer Institute (NCI), National Institutes of Health (NIH) |
| NCT00103142 | Phase 2 | Feb 1, 2005 | Duke University, National Cancer Institute (NCI) |
| NCT00088413 | Phase 1 | Jul 20, 2004 | National Cancer Institute (NCI) |
| NCT00088660 | Phase 3 | Jun 1, 2004 | Therion Biologics Corporation |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Government | 5 | 4 | 2 | 2004 |
| Rutgers University | Academic/Hospital | 2 | 0 | 2 | 2010 |
| Duke University | Academic/Hospital | 1 | 1 | 1 | 2005 |
| National Institutes of Health (NIH) | Government | 1 | 0 | 1 | 2005 |
| Therion Biologics Corporation | For profit | 1 | 1 | 1 | 2004 |
5 organizations
Page 1 / 1